GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Total Inventories
Switch to:

Biogen (MEX:BIIB) Total Inventories

: MXN23,090 Mil (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Biogen's total inventories for the quarter that ended in Mar. 2023 was MXN23,090 Mil. Biogen's average total inventories from the quarter that ended in Dec. 2022 to the quarter that ended in Mar. 2023 was MXN24,650 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Biogen's Net-Net Working Capital per share for the quarter that ended in Mar. 2023 was MXN-447.99.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biogen's Days Inventory for the three months ended in Mar. 2023 was 188.28.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biogen's Inventory Turnover for the quarter that ended in Mar. 2023 was 0.48.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biogen's Inventory-to-Revenue for the quarter that ended in Mar. 2023 was 0.56.


Biogen Total Inventories Historical Data

The historical data trend for Biogen's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Inventories
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,258.59 15,167.21 21,256.59 27,724.67 26,210.42

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Inventories Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24,199.83 26,036.72 27,658.13 26,210.42 23,090.03

Biogen Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Biogen  (MEX:BIIB) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Biogen's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2023 is

Net-Net Working Capital Per Share (Q: Mar. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(90869.432+0.75 * 36558.305+0.5 * 23090.025-194875.485
-0--173.04)/144.8
=-447.99

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biogen's Days Inventory for the three months ended in Mar. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2023 )/Cost of Goods Sold (Q: Mar. 2023 )*Days in Period
=24650.2235/11946.97*365 / 4
=188.28

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biogen's Inventory Turnover for the quarter that ended in Mar. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2023 ) / Average Total Inventories (Q: Mar. 2023 )
=11946.97 / 24650.2235
=0.48

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biogen's Inventory to Revenue for the quarter that ended in Mar. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=24650.2235 / 44395.575
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Biogen Total Inventories Related Terms

Thank you for viewing the detailed overview of Biogen's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines